Teva and Sanofi report sustained 44‑week Phase 2b data for duvakitug in ulcerative colitis and Crohn’s disease
Teva Pharmaceuticals and Sanofi presented 44‑week long‑term extension results for duvakitug, an investigational TL1A‑targeting antibody, in patients with moderately‑to‑severely active ulcerative colitis (UC) and Crohn’s disease (CD). The study enrolled 130 responders from a prior 14‑week induction, randomising them to 450 mg or 900 mg subcutaneously every four weeks. Across both indications, higher doses yielded numerically better remission, response and endoscopic improvement rates, and the safety profile remained consistent with earlier phases.
Why it matters
The companies said the data support progression of duvakitug into Phase 3 trials, which could enhance the value of their IBD pipelines if the drug eventually gains regulatory approval. Investors may see the results as a catalyst for future market‑based upside in the biotech segment.
Key facts
- 1The RELIEVE UCCD LTE study included 130 patients, of whom 72 had UC and 58 had CD. investingnews.com
- 2Patients were randomised to receive duvakitug 450 mg or 900 mg subcutaneously every four weeks. investingnews.com
- 3In UC, clinical remission at Week 44 was 47% with 450 mg and 58% with 900 mg. rttnews.com
- 4In CD, clinical remission at Week 44 was 81% with 450 mg and 84% with 900 mg. rttnews.com
- 5Discontinuation due to adverse events was low (UC 4% and 2% for 450 mg and 900 mg; CD 6% in each arm). investingnews.com
- 6The maintenance period lasted 44 weeks. investingnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.